Ascelia Pharma re-evaluation outcome: SPARKLE meet primary endpoints - Redeye

Orviglance meets the primary endpoint in the SPARKLE study with a p-value of <0.001. Equally important in this situation is that ” The reliability of the data is solid and conclusive for all readers – this includes an acceptable level of variability”. We look forward to further details and clarifications on the call scheduled for 7 May (CET 14.00).

Länk till analysen i sin helhet: https://www.redeye.se/research/1001939/ascelia-pharma-re-evaluation-outcome-sparkle-meet-primary-endpoints?utm_source=finwire&utm_medium=RSS